Healthcare Providers and Services
Company Overview of Bio-Reference Laboratories Inc.
Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases in the United States. The company focuses on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional health care services. It offers chemical diagnostic tests, such as blood and urine analysis; blood chemistry; hematology services; serology; radio-immuno analysis; toxicology, including drug screening; pap smears; tissue pathology comprising biopsies; and other tissue analysis, as well as cancer cytogenetic testing, genetic testing, and cytology testing services. The company also operate...
481 Edward H. Ross Drive
Elmwood Park, NJ 07407
Founded in 1981
Key Executives for Bio-Reference Laboratories Inc.
Chief Operating Officer and Executive Vice-President
President of Careevolve and Chief Operating Officer of Careevolve
VP & Chief Compliance Officer
Compensation as of Fiscal Year 2017.
Bio-Reference Laboratories Inc. Key Developments
BioReference Laboratories Appoints Sandra Cole as Vice President and Chief Compliance Officer
Sep 7 17
BioReference Laboratories announced the election of Sandra Cole as its vice president and chief compliance officer. In the new senior positions, Cole will lead and oversee company-wide restructuring of compliance and privacy programmes, core compliance processes, risk assessments, metrics, analytics as well as corporate policy, with responsibility for the entire department. Prior to the promotion, Cole has served as the compliance and privacy officer at the company.
BioReference Laboratories Appoints Victoria L. Laughman as Executive Vice President of Sales
Aug 17 17
BioReference Laboratories announced the appointment of Victoria L. Laughman as Executive Vice President of Sales. With more than two decades of industry experience, including a stint at BioReference's GeneDx genetics division, Ms. Laughman will lead a national sales force from BioReference's corporate headquarters in Elmwood Park, NJ. Prior to her new post, Ms. Laughman previously served as director of physician outreach and development for the John Muir Health System in California; she was also the president and founder of Caretinuum LLC. As VP of sales, Ms. Laughman will lead a national sales force of more than 400, providing physician clients, hospitals and health systems a one-stop shop for services from routine testing to highly-specialized esoteric assays.
Diaceutics Announces Five-Year Partnership with BioReference Laboratories
Apr 24 17
Diaceutics announced five-year partnership with BioReference Laboratories. The exclusive partnership will see Diaceutics acquire real-time testing data from BioReference, allowing it to help pharmaceutical companies achieve faster rollouts of new drugs through better understanding of the US diagnostics market. Through its partnership with BioReference, which works with 30,000 healthcare providers across the US, Diaceutics will have access to data from 50,000 patient samples per day. Coupled with insights from BioReference, the real-time data will help improve patient testing by ensuring that pharmaceutical companies better understand the testing patterns of physicians considering precision medicine therapies for patients. Currently, Diaceutics estimates that pharmaceutical companies are missing out on more than 12% of cancer patients every year in the US alone due to poor diagnostic planning. With 70% of new drugs in the next five years expected to be test-dependent, Diaceutics expects that percentage will increase. Diaceutics will integrate the data gathered from BioReference with its existing data sets accumulated through partnerships with other labs. Together, the data will allow Diaceutics to provide Pharma with more complete, aggregated testing data that meets their very specific requirements and helps them close the 12% patient gap in the oncology testing market and achieve a better return on new drug investments.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|